



ASSET VALUATION & DUE DILIGENCE

Understand and articulate the market value of your asset

Create a differentiated value story.

Drive investor and partnering discussions for optimal outcomes.

As you progress through the various stages of drug development and commercialization, you will need to address how your asset brings value to the industry, your stakeholders and your company.



KEY CHALLENGES


- Conducting technical and commercial due diligence to define the market opportunity, investment costs, and development risks
- Building a risk-adjusted NPV valuation model detailing revenue and investments scenarios
- Gathering unique local perspective from global and emerging markets
- Articulating asset value through a clear and differentiated value story
- Creating compelling pitch decks and materials to share with investors and potential partners
- Identifying strategic options, including deal, partnering, and commercialization pathways

WAYS WE CAN HELP

- Early assessment of product feasibility
- Integrated technical and commercial due diligence
- Asset risk profiling
- **⊘** Value inflection mapping
- Asset and portfolio valuation
- O Deal option and structure assessment
- ✓ Value proposition and pitch materials

Asset Valuation & Due Diligence is only one of the ways IQVIA™ Biotech can help you advance your asset. We offer a comprehensive set of flexible solutions that can be customized to your specific needs, meeting you where you are in the development journey.

Spanning strategic consulting, clinical development, product launch and commercialization



IQVIA Biotech's five key solution areas – Asset Valuation & Due Diligence, Drug Development Strategy & Analytics, Clinical Development, Launch Strategy & Planning, and Commercialization & Lifecycle Management – support you at different milestones in your journey. Our suite of flexible solutions enable you to pick and choose what's right for you. No matter where you are in your development or commercialization journey, IQVIA Biotech can help you advance your asset with confidence and credibility.

ACTIVITIES FOR THE ASSET VALUATION & DUE DILIGENCE MILESTONES

PRE-CLINICAL VALIDATION

- · Asset valuation
- · Technical evaluation
- IND/CTA gap analysis

IND/CTA SUBMISSION

- Pre-IND/Scientific advice meeting
- Protocol writing
- Planning for accelerated designations

PHASE I IMPLEMENTATION

- TPP/Clinical development planning
- · Assess safety profile
- Early proof of concept

PHASE II IMPLEMENTATION

- · Proof of concept confirmed
- · Adaptive approaches for Phase III
- End of Phase II agency meeting

IQVIA Biotech can help you strengthen your position with investors and partners, and advance the value of your asset.

